Abstract

Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.

Details

Title
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
Author
Corwin, Douglas S 1 ; Ender, Peter T 2 ; Sahu, Nitasa 1 ; Durgham, Ryan A 3 ; McGorry, Dennis M, Jr 4 ; Awan Rahman 1 ; Stoltzfus, Jill 5 ; Jahre, Jeffrey A 2 

1  Section of Pulmonary and Critical Care, Department of Medicine, St Luke’s University Health Network, Bethlehem, Pennsylvania, USA 
2  Section of Infectious Diseases, Department of Medicine, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA 
3  Temple/St. Luke’s School of Medicine, Bethlehem, Pennsylvania, USA 
4  Department of Family Medicine, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA 
5  Graduate Medical Education, Data Management and Outcomes Assessment, St. Luke’s University Health Network, Bethlehem, Pennsylvania, USA 
Publication year
2021
Publication date
Jul 2021
Publisher
Oxford University Press
e-ISSN
23288957
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1093/ofid/ofab305
ProQuest document ID
3170947903
Copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.